Placebo News and Research

RSS

Using corticosteroids before late preterm delivery reduces respiratory complications in babies

A multicenter clinical trial led by researchers at Columbia University Medical Center and NewYork-Presbyterian has found that the use of corticosteroids in mothers at risk for late preterm delivery significantly reduced the incidence of severe respiratory complications in their babies.

5 Feb 2016

Noninvasive FMRI may help evaluate effectiveness of new pain medications

New research may allow new, more effective and safer pain medications to reach patients who suffer from chronic pain sooner. According to a recent study published in Anesthesiology, the official medical journal of the American Society of Anesthesiologists, using functional magnetic resonance imaging (FMRI), to measure the brain's neural response to pain, may be a viable tool for evaluating the effectiveness of new pain medications during the early stages of human drug development - providing the needed objective evidence to prevent the premature discarding of potentially beneficial therapies.

4 Feb 2016

NICE recommends Xofigo (radium-223 dichloride) for prostate cancer patients after treatment with docetaxel

The National Institute for Health and Care Excellence has issued its final guidance recommending Xofigo for use on the NHS in England and Wales as an option for treating adult men, with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases, who have received previous docetaxel therapy.

4 Feb 2016

UCI researchers identify potential strategies to prevent cognitive decline

As brain cells age they lose the fibers that receive neural impulses, a change that may underlie cognitive decline. Researchers at the University of California, Irvine recently found a way to reverse this process in rats. The study was published February 3 in The Journal of Neuroscience. Researchers caution that more studies are needed, but the findings shed light on the mechanisms of cognitive decline and identify potential strategies to stem it.

3 Feb 2016

Use of antenatal steroids during late preterm delivery prevents neonatal respiratory complications

In a study to be presented on Feb. 4 in the oral plenary session at 8 a.m. EST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, in Atlanta, researchers with the Eunice Kennedy Shriver National Institute of Child Health and Human Development and Maternal-Fetal Medicine Units Network found that the administration of antenatal steroids in pregnancies at risk for late preterm delivery prevents respiratory and other neonatal complications.

2 Feb 2016

Unobtrusive patch on the forehead provides relief from PTSD

An average of 30 years had passed since the traumatic events that had left them depressed, anxious, irritable, hypervigilant, unable to sleep well and prone to nightmares.

30 Jan 2016

Fingolimod trial INFORMS primary progressive MS strategy

Fingolimod is unable to slow disability progression or brain volume loss in patients with primary progressive multiple sclerosis, show the findings of the INFORMS study.

29 Jan 2016

Neuroprotection powers for phenytoin in acute optic neuritis

Selective sodium channel blockade with the anti-epileptic drug phenytoin protects against acute demyelinating optic neuritis, researchers report.

29 Jan 2016

RegeneRx Biopharmaceuticals announces completion of enrollment for Phase 2b/3 dry eye trial in U.S.

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture with G-treeBNT, ReGenTree LLC, has completed enrollment of its Phase 2b/3 dry eye trial in the U.S.

29 Jan 2016

AbbVie announces initiation of first Elagolix Phase 3 study in patients with uterine fibroid

AbbVie, in cooperation with Neurocrine Biosciences, Inc., today announced the initiation of the first of two planned Phase 3 clinical studies evaluating the safety and efficacy of Elagolix alone or in combination with add-back therapy compared to placebo.

29 Jan 2016

Dysport phase III study results in children with cerebral palsy with lower limb spasticity published in Pediatrics

Ipsen today announced that the scientific journal Pediatrics published the detailed results of the phase III randomized study showing both the efficacy and the safety of Dysport in the treatment of dynamic equinus foot deformity, a condition associated with cerebral palsy in children.

28 Jan 2016

NTCELL stops Parkinson’s disease progression one year after treatment

Over a year after treatment all four patients who took part in Living Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL® for Parkinson’s disease remain well, and at 58 weeks post-implant there are no safety concerns.

28 Jan 2016

10 million of us lack sunshine vitamin

Health pioneers BetterYou have welcomed the views of Nutritionist Marilyn Glenville, that ‘oil based supplements can help you get your recommended dose of vitamin D’.

From BetterYou Ltd 27 Jan 2016

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.

27 Jan 2016

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.

27 Jan 2016

Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Shire plc today announced it has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration for its investigational candidate, lifitegrast, for the treatment of signs and symptoms of dry eye disease in adults. Shire resubmitted the NDA in response to the complete response letter (CRL) the company received from the FDA on October 16, 2015.

25 Jan 2016

Chronic exposure to environmental toxin may up risk of neurodegenerative illness

A new study published today in the science journal Proceedings of the Royal Society B indicates that chronic exposure to an environmental toxin may increase risk of neurodegenerative illness. Conducted by scientists at the Institute for EthnoMedicine, a non-profit medical research organization, and the University of Miami Brain Endowment Bank, the study provides a foundation for future research in Alzheimer's disease, ALS and Parkinson's disease.

25 Jan 2016

Researchers use ASC secreted factors to create therapeutic factor concentrate for critical limb ischemia

"Critical limb ischemia" (CLI) describes an advanced stage of peripheral artery disease characterized by obstruction of the arteries and a markedly reduced blood flow to the extremities. CLI identifies patients at high-risk for major amputation. The estimated annual incidence of CLI ranges between 500 and 1000 new cases out of one million people per year, with the highest rates among the elderly, smokers, and those with diabetes. CLI is considered to be a critical public health issue. Attempts at revascularization are often unsuccessful.

22 Jan 2016

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in Japan.

22 Jan 2016

Aged Garlic Extract beneficial for preventing heart disease

The supplement Aged Garlic Extract can reverse the buildup of deadly plaque in arteries and help prevent the progression of heart disease, according to a new study scheduled for publication in the Journal of Nutrition.

22 Jan 2016

Placebo News and Research

Using corticosteroids before late preterm delivery reduces respiratory complications in babies

Noninvasive FMRI may help evaluate effectiveness of new pain medications

NICE recommends Xofigo (radium-223 dichloride) for prostate cancer patients after treatment with docetaxel

UCI researchers identify potential strategies to prevent cognitive decline

Use of antenatal steroids during late preterm delivery prevents neonatal respiratory complications

Unobtrusive patch on the forehead provides relief from PTSD

Fingolimod trial INFORMS primary progressive MS strategy

Neuroprotection powers for phenytoin in acute optic neuritis

RegeneRx Biopharmaceuticals announces completion of enrollment for Phase 2b/3 dry eye trial in U.S.

AbbVie announces initiation of first Elagolix Phase 3 study in patients with uterine fibroid

Dysport phase III study results in children with cerebral palsy with lower limb spasticity published in Pediatrics

NTCELL stops Parkinson’s disease progression one year after treatment

10 million of us lack sunshine vitamin

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Chronic exposure to environmental toxin may up risk of neurodegenerative illness

Researchers use ASC secreted factors to create therapeutic factor concentrate for critical limb ischemia

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Aged Garlic Extract beneficial for preventing heart disease

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News